Corbus Pharmaceuticals - CRBP Stock Forecast, Price & News

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Corbus Pharmaceuticals in the last twelve months. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" CRBP shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CRBP, but not buy additional shares or sell existing shares.
View CRBP analyst ratings or view top-rated stocks.

3 Wall Street analysts have issued 1 year price targets for Corbus Pharmaceuticals' shares. Their CRBP share price forecasts range from $2.00 to $3.00. On average, they anticipate the company's stock price to reach $2.50 in the next year. This suggests a possible upside of 873.9% from the stock's current price.
View analysts price targets for CRBP or view top-rated stocks among Wall Street analysts.

Corbus Pharmaceuticals' stock was trading at $0.6157 at the beginning of the year. Since then, CRBP shares have decreased by 58.3% and is now trading at $0.2567.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Friday, November 11th 2022.
View our CRBP earnings forecast.

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) announced its quarterly earnings data on Friday, November, 12th. The biopharmaceutical company reported ($0.02) earnings per share for the quarter, beating analysts' consensus estimates of ($0.12) by $0.10. The biopharmaceutical company had revenue of $0.10 million for the quarter, compared to analyst estimates of $0.81 million.

Based on aggregate information from My MarketBeat watchlists, some companies that other Corbus Pharmaceuticals investors own include Visa (V), HP (HPQ), Fortive (FTV), Lowe's Companies (LOW), Sorrento Therapeutics (SRNE), Exelixis (EXEL), Matinas BioPharma (MTNB), Inovio Pharmaceuticals (INO) and KushCo (KSHB).

Corbus Pharmaceuticals trades on the NASDAQ under the ticker symbol "CRBP."

Corbus Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional investors include Mirae Asset Global Investments Co. Ltd. (3.22%), Renaissance Technologies LLC (1.30%), Ikarian Capital LLC (0.69%), Group One Trading L.P. (0.00%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Barbara White, Craig Stuart Millian, Robert Paul Discordia, Sean F Moran and Yuval Cohen.
View institutional ownership trends.

Shares of CRBP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of CRBP stock can currently be purchased for approximately $0.26.

Corbus Pharmaceuticals (NASDAQ:CRBP) has a market capitalization of $32.16 million and generates $880,000.00 in revenue each year. The biopharmaceutical company earns $-45,640,000.00 in net income (profit) each year or ($0.29) on an earnings per share basis.

Corbus Pharmaceuticals' mailing address is 500 River Ridge Drive, Norwood MA, 02062. The official website for the company is www.corbuspharma.com. The biopharmaceutical company can be reached via phone at (617) 963-0100, via email at ir@corbuspharma.com, or via fax at 617-663-6085.